Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A)

por Prukop, Thomas, Stenzel, Jan, Wernick, Stephanie, Kungl, Theresa, Mroczek, Magdalena, Adam, Julia, Ewers, David, Nabirotchkin, Serguei, Nave, Klaus-Armin, Hajj, Rodolphe, Cohen, Daniel, Sereda, Michael W.
Publicado 2019

Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A

por Rafehi, Muhammad, Faltraco, Frank, Matthaei, Johannes, Prukop, Thomas, Jensen, Ole, Grytzmann, Aileen, Blome, Felix G., Berger, Ralf Günter, Krings, Ulrich, Vormfelde, Stefan V., Tzvetkov, Mladen V., Brockmöller, Jürgen
Publicado 2019

Curcumin therapy in a Plp1 transgenic mouse model of Pelizaeus-Merzbacher disease

por Epplen, Dirk B, Prukop, Thomas, Nientiedt, Tobias, Albrecht, Philipp, Arlt, Friederike A, Stassart, Ruth M, Kassmann, Celia M, Methner, Axel, Nave, Klaus-Armin, Werner, Hauke B, Sereda, Michael W
Publicado 2015

Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy

por Fledrich, R., Abdelaal, T., Rasch, L., Bansal, V., Schütza, V., Brügger, B., Lüchtenborg, C., Prukop, T., Stenzel, J., Rahman, R. U., Hermes, D., Ewers, D., Möbius, W., Ruhwedel, T., Katona, I., Weis, J., Klein, D., Martini, R., Brück, W., Müller, W. C., Bonn, S., Bechmann, I., Nave, K. A., Stassart, R. M., Sereda, M. W.
Publicado 2018